CJC-1295 + Ipamorelin refers to a pairing of two synthetic peptides studied for their effects on growth hormone signaling. CJC-1295 belongs to the growth hormone–releasing hormone analog family, while ipamorelin acts through the growth hormone secretagogue receptor, also known as the ghrelin receptor.

Although these compounds are frequently discussed together, their individual research histories are different. Understanding the combination requires separating laboratory findings, early human studies, and claims that have not been established through clinical research. A change in growth hormone levels does not, by itself, demonstrate a health benefit. PubMed

For an introduction to peptide structure and terminology, read What Are Peptides?.

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone–releasing hormone, commonly abbreviated GHRH. Researchers developed it to investigate prolonged stimulation of the pathway that regulates growth hormone release.

The long-acting form studied in early human trials includes a drug affinity complex, or DAC. This modification enables binding to circulating albumin, extending the compound’s presence in the bloodstream.

A 2006 study by Teichman and colleagues evaluated long-acting CJC-1295 in healthy adults. Researchers observed sustained increases in growth hormone and insulin-like growth factor 1, or IGF-1. These findings demonstrated biological activity; they did not establish the compound as an effective treatment for aging, weight management, or athletic recovery. fda.gov

CJC-1295 With DAC vs. Without DAC

The name “CJC-1295” can be confusing because commercial discussions do not always distinguish between different forms.

Term	Important distinction
CJC-1295 with DAC	Includes an albumin-binding modification and is the long-acting form evaluated in the frequently cited early clinical studies.
CJC-1295 without DAC	Commonly used commercially for modified GRF(1–29), a related peptide without the albumin-binding modification.
CJC-1295 + Ipamorelin	Describes a pairing but does not identify whether the CJC component includes DAC.

These names should not be treated as interchangeable. Findings about duration of action or hormone responses from DAC-containing CJC-1295 cannot automatically be applied to a material labeled “without DAC.” The FDA’s review of CJC-1295-related substances separately examines these chemical forms. fda.gov

For related background on GHRH analogs, see What Is Sermorelin? and What Is Tesamorelin?.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide, meaning it contains five amino acid residues. It is classified as a growth hormone secretagogue—a compound investigated for its ability to stimulate growth hormone release.

Unlike a GHRH analog, ipamorelin acts through the ghrelin receptor pathway.

In the foundational 1998 study by Raun and colleagues, researchers examined ipamorelin in laboratory and animal models. The compound stimulated growth hormone release and showed selectivity relative to certain other hormone responses under the tested conditions.

That selectivity is an experimental finding, not proof that ipamorelin has no side effects in humans. PubMed

Why Are CJC-1295 and Ipamorelin Discussed Together?

The scientific rationale concerns their different receptor targets:

• CJC-1295: acts through the GHRH pathway.
• Ipamorelin: acts through the ghrelin receptor pathway.

Because these pathways both participate in growth hormone regulation, combining agents that act through them raises questions about how their effects might interact.

However, a plausible mechanism is not the same as demonstrated effectiveness. Research on one peptide, or on other combinations of hormone-releasing agents, does not establish the outcomes of a specific CJC-1295 + Ipamorelin formulation.

The studies discussed below primarily evaluated the individual compounds. They should not be presented as clinical validation of the combination. PubMed

What Does the Research Actually Show?

1. CJC-1295 Has Demonstrated Hormonal Activity in Humans

The Teichman study reported increases in growth hormone and IGF-1 after administration of long-acting CJC-1295.

Its central contribution was evidence about hormone responses, pharmacokinetics, and short-term tolerability. It did not evaluate a CJC-1295 + Ipamorelin blend or establish long-term clinical benefits from that combination. PubMed

2. Growth Hormone Pulses Can Persist During Long-Acting CJC-1295 Exposure

A separate study by Ionescu and Frohman examined growth hormone secretion during prolonged stimulation with CJC-1295.

Researchers found that pulsatile secretion persisted. This contributes to understanding how long-acting GHRH stimulation affects hormone patterns, but preserved pulsatility alone does not establish safety or improved health outcomes. PubMed

3. Ipamorelin Has Been Studied in Human Volunteers

A 1999 pharmacokinetic and pharmacodynamic study investigated ipamorelin in healthy volunteers.

This type of research examines how exposure to a compound relates to a measurable biological response. It helps characterize the compound but does not establish that combining it with CJC-1295 improves sleep, body composition, or recovery. pubmed.ncbi.nlm.nih.gov

4. Ipamorelin’s Gastrointestinal Research Had Mixed Translational Results

Researchers have also studied ipamorelin in the context of gastrointestinal motility. A rodent study of postoperative ileus investigated its effects after surgery.

A subsequent randomized human trial published in 2014 evaluated intravenous ipamorelin in patients undergoing bowel resection. The trial did not find statistically significant differences between ipamorelin and placebo in its key and secondary efficacy analyses.

This illustrates why promising biological activity must be distinguished from demonstrated clinical effectiveness. The study also concerned ipamorelin alone, a specific administration route, and a surgical population—not the CJC-1295 + Ipamorelin combination. PubMed

What Has Not Been Established About the Combination?

The cited studies do not establish CJC-1295 + Ipamorelin as an effective intervention for:

• Increasing muscle mass or strength in healthy adults.
• Producing sustained fat loss.
• Improving sleep quality.
• Accelerating injury recovery.
• Reversing aging.
• Providing safe long-term growth hormone stimulation.

These are distinct outcomes requiring appropriately designed studies of the actual combination.

Hormone measurements are biological markers. They are not substitutes for measuring meaningful benefits and adverse effects. Claims about the combination should therefore identify exactly which formulation, population, and outcome were studied. PubMed

Safety and Regulatory Considerations

CJC-1295 and ipamorelin are not FDA-approved drugs. Their availability as research materials does not establish approval for human treatment. FDA

The FDA’s safety information on substances used in compounding identifies concerns involving both compounds.

For CJC-1295, the agency describes limited clinical data, potential immunogenicity concerns, and serious adverse events associated with increased heart rate and systemic vasodilatory reactions.

For ipamorelin acetate, FDA identifies concerns involving peptide aggregation, impurities, and inadequate safety information for certain injectable routes. The agency also notes serious adverse events, including deaths, in an intravenous study. The occurrence of these events does not by itself establish that ipamorelin caused them; FDA’s advisory materials acknowledge uncertainty about that relationship. FDA

Terms such as “selective,” “research grade,” or “high purity” should not be interpreted as proof of clinical safety.

Why Chemical Identity and Analytical Documentation Matter

For laboratory research, the name on a label is only the starting point. Relevant documentation should make the identity and composition of the material clear.

When evaluating a CJC-1295 + Ipamorelin research material, useful questions include:

• Does the CJC-1295 component contain DAC?
• Are both components and their stated quantities identified?
• Does the analytical documentation correspond to the specific batch?
• Which tests were performed, and what does each result establish?
• Does the documentation distinguish identity, purity, and quantity?

A purity percentage alone does not answer all these questions or establish suitability for human administration.

For more detail, read HPLC vs. LC-MS: Understanding Peptide Purity and Identity Testing and Peptide Certificate of Analysis: How to Read a COA.

Frequently Asked Questions

Is CJC-1295 + Ipamorelin one peptide?

No. The name describes two separate peptides discussed or formulated together. Their receptor targets and research histories differ. PubMed

Is CJC-1295 without DAC the same as CJC-1295 with DAC?

No. The albumin-binding modification is a meaningful chemical distinction. Research findings should be matched to the actual form studied. fda.gov

Does research on each peptide prove that the combination works?

No. Individual-compound studies cannot establish the effectiveness, interactions, or long-term safety of a combination. The studies cited here do not validate the blend for common claims involving muscle growth, fat loss, sleep, or anti-aging. PubMed

Where can I learn more about research peptides?

Visit our Research Library or read What Are Research Peptides? for additional background.

This article is for scientific education only. It does not provide medical advice or instructions for administration. Materials offered by Peptides Exchange are intended for laboratory research only and are not for human or animal use.

Sources and Further Reading

1. Teichman et al., 2006: Human study of long-acting CJC-1295 and GH/IGF-1 secretion.
2. Ionescu and Frohman, 2006: Pulsatile growth hormone secretion during CJC-1295 stimulation.
3. Raun et al., 1998: Foundational research on ipamorelin’s secretagogue activity.
4. Human volunteer study, 1999: Pharmacokinetic-pharmacodynamic modeling of ipamorelin.
5. Preclinical gastrointestinal research: Ipamorelin in a rodent model of postoperative ileus.
6. Beck et al., 2014: Randomized trial of ipamorelin following bowel resection.
7. FDA: Review of CJC-1295-related bulk drug substances.
8. FDA: Compounding substances that may present significant safety risks.
9. FDA: Ipamorelin advisory committee presentation and safety assessment.